Medicare Enrolled
Dr. Hooman Ranjbaran-Jahromi, M.D.
Cardiovascular Disease · Liverpool, NY
Practice pattern: Cardiac & Remote
— Practice combining cardiac and remote services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ranjbaran-Jahromi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ranjbaran-Jahromi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ranjbaran-Jahromi
Dr. Hooman Ranjbaran-Jahromi is a cardiovascular disease specialist in Liverpool, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ranjbaran-Jahromi performed 5,077 Medicare services across 3,644 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ranjbaran-Jahromi received a total of $6,968 from 41 pharmaceutical and/or device companies across 448 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ranjbaran-Jahromi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in NY
$6,968 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,077
Medicare services
Top 12% in NY for cardiovascular disease
3,644
Unique beneficiaries
$57
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~267 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,342 | $88 | $155 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
606 | $9 | $65 |
| EKG interpretation and report A standard electrocardiogram test that records the heart's electrical activity using at least 12 leads. The service includes a professional interpretation of the results and a written report. |
437 | $6 | $29 |
| Echocardiogram, transthoracic An ultrasound of the heart that uses color to show blood flow, rate, direction, and valve function. |
426 | $128 | $495 |
| Regadenoson injection (Lexiscan) for heart stress test An injection of regadenoson, a medication used to stress the heart during diagnostic testing. |
408 | $22 | $29 |
| Remote monitoring of implantable heart device, up to 30 days Remote evaluation of an implanted heart or blood vessel monitoring system over a period of up to 30 days. |
316 | $19 | $50 |
| Technetium Tc-99m sestamibi diagnostic injection A diagnostic injection of technetium Tc-99m sestamibi used for imaging studies. |
245 | $24 | $32 |
| Remote cardiac rhythm monitor evaluation, up to 30 days Review and analysis of data from a remote cardiac rhythm monitoring system over a period of up to 30 days. |
222 | $18 | $60 |
| Remote pacemaker monitoring, 90 days Remote assessment of a pacemaker system, including single, dual, multiple lead, or leadless devices, performed up to 90 days apart. |
212 | $20 | $75 |
| Exercise or drug-induced heart stress test with ECG A heart stress test performed using exercise or medication while monitoring the electrocardiogram under physician supervision and review. |
128 | $48 | $300 |
| Nuclear stress test of heart muscle A nuclear medicine imaging test that evaluates blood flow to the heart muscle at rest and during stress using a special camera. |
120 | $312 | $1,000 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
110 | $67 | $105 |
| Remote evaluation of implantable defibrillator system Remote assessment of a single, dual, or multiple lead implantable defibrillator system within 90 days of the previous evaluation. |
96 | $27 | $130 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
66 | $112 | $230 |
| Echocardiogram, transthoracic An ultrasound test that uses sound waves to create images of the heart's blood flow, valves, and chambers. |
52 | $38 | $225 |
| Echocardiogram with color Doppler An ultrasound of the heart that uses color imaging to visualize blood flow, measure flow rate, and assess valve function. |
52 | $17 | $225 |
| Stress echocardiogram with ECG monitoring An ultrasound of the heart performed while monitoring heart rhythm during rest, exercise, or medication-induced stress, followed by a review and report of the findings. |
46 | $150 | $525 |
| Continuous ECG monitoring, up to 30 days Continuous heart rhythm monitoring for up to 30 days, including professional review and reporting of the results. |
41 | $19 | $55 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
24 | $61 | $135 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
23 | $14 | $30 |
| 2-day continuous ECG monitoring A continuous electrocardiogram recording that captures heart activity over a 48-hour period. This test helps detect irregular heart rhythms or other cardiac issues that may not appear during a standard, short-term ECG. |
21 | $12 | $95 |
| 2-day continuous ECG with professional review A two-day continuous electrocardiogram recording that includes a review by a healthcare professional. |
21 | $12 | $110 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
20 | $128 | $205 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
19 | $99 | $255 |
| Continuous external EKG monitoring, 48 hours to 7 days This procedure involves recording the heart's electrical activity continuously using an external device for a period exceeding 48 hours but not more than 7 days. |
12 | $9 | $30 |
| Continuous EKG monitoring review, 48-7 days Review and interpretation of continuous external EKG recordings lasting more than 48 hours up to 7 days. |
12 | $18 | $50 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
15.5% high complexity
19.7% medium
64.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,968
Total received (2018-2024)
Avg $995/year across 7 years
Top 26% in NY for cardiovascular disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
448
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,968 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$893
2023
$874
2022
$1,570
2021
$690
2020
$548
2019
$1,301
2018
$1,091
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$178
Amgen Inc.
$83
ABIOMED
$71
E.R. Squibb & Sons, L.L.C.
$68
Kiniksa Pharmaceuticals International, plc
$67
Janssen Pharmaceuticals, Inc
$64
Boston Scientific Corporation
$59
Daiichi Sankyo Inc.
$50
Regeneron Healthcare Solutions, Inc.
$41
Boehringer Ingelheim Pharmaceuticals, Inc.
$41
Medtronic, Inc.
$23
Actelion Pharmaceuticals US, Inc.
$22
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$20
Edwards Lifesciences Corporation
$19
Merck Sharp & Dohme LLC
$19
SCPHARMACEUTICALS INC.
$19
PFIZER INC.
$16
Lexicon Pharmaceuticals, Inc.
$16
Novo Nordisk Inc
$15
Top 3 companies account for 37.3% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,223
Janssen Pharmaceuticals, Inc
$736
Novartis Pharmaceuticals Corporation
$666
Boehringer Ingelheim Pharmaceuticals, Inc.
$494
E.R. Squibb & Sons, L.L.C.
$387
Regeneron Healthcare Solutions, Inc.
$377
SANOFI-AVENTIS U.S. LLC
$349
Amarin Pharma Inc.
$342
Boston Scientific Corporation
$249
PFIZER INC.
$241
Edwards Lifesciences Corporation
$223
Merck Sharp & Dohme LLC
$219
AstraZeneca Pharmaceuticals LP
$132
Actelion Pharmaceuticals US, Inc.
$130
Bayer HealthCare Pharmaceuticals Inc.
$103
ABIOMED
$101
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$96
Kowa Pharmaceuticals America, Inc.
$84
BOSTON SCIENTIFIC CORPORATION
$76
BIOTRONIK INC.
$74
Lexicon Pharmaceuticals, Inc.
$68
Kiniksa Pharmaceuticals International, plc
$67
Medtronic, Inc.
$56
Kiniksa Pharmaceuticals, Ltd.
$51
Daiichi Sankyo Inc.
$50
SCPHARMACEUTICALS INC.
$48
Novo Nordisk Inc
$43
Esperion Therapeutics, Inc.
$38
Alnylam Pharmaceuticals Inc.
$31
GENZYME CORPORATION
$25
Allergan Inc.
$23
Gilead Sciences, Inc.
$23
iRhythm Technologies, Inc.
$22
Astellas Pharma US Inc
$19
Philips Electronics North America Corporation
$18
Akcea Therapeutics, Inc.
$16
MEDICOMP INC
$15
Medtronic Vascular, Inc.
$15
Abbott Laboratories
$14
ARBOR PHARMACEUTICALS, INC.
$13
Merck Sharp & Dohme Corporation
$12
Top 3 companies account for 37.7% of all-time payments
Associated products mentioned in payments ›
Adempas · Arcalyst · Assurity Pacemaker · BELSOMRA · BRILINTA · BYSTOLIC · CAMZYOS · COBALT DR MRI SURESCAN · Cardiac Monitor · Claria MRI · Corlanor · ELIQUIS · EMBLEM · ENTRESTO · EPIQ 7C · EVKEEZA · Edarbi · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · FABRAZYME · FARXIGA · FUROSCIX · GENERAL THERAPIES · INJECTAFER · Impella · Inpefa · JARDIANCE · Kerendia · LEQVIO · LEXISCAN · LINQ II · LifeVest · Livalo · MICRA · MULTAQ · NEXLETOL · ONPATTRO · OPSUMIT · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Repatha · SAPIEN 3 Ultra RESILIA · TEGSEDI · UPTRAVI · VERQUVO · VYNDAQEL · Vascepa · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · Wegovy · XARELTO · ZIO XT Patch
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Cardiologists within 10 mi
71
Per 100K population
15.1
County median income
$74,740
Nearest hospital
ST JOSEPH'S HOSPITAL HEALTH CENTER
4.3 mi
4.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ranjbaran-Jahromi is a cardiac & remote specialist, with above-average Medicare volume (top 12% in NY), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ranjbaran-Jahromi experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Ranjbaran-Jahromi performed 1,342 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ranjbaran-Jahromi receive payments from pharmaceutical companies?
Yes. Dr. Ranjbaran-Jahromi received a total of $6,968 from 41 companies across 448 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ranjbaran-Jahromi's costs compare to other cardiologists in Liverpool?
Dr. Ranjbaran-Jahromi's average Medicare payment per service is $57. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ranjbaran-Jahromi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiologists in Liverpool
Browse cardiologists in Liverpool ranked by procedure volume and transparency data.
Highest volume
Top Cardiologists in NY
Cardiologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiologists in NY
Which NY cardiologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology